144
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).

          Related collections

          Author and article information

          Journal
          Lancet Oncol
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          Feb 2014
          : 15
          : 2
          Affiliations
          [1 ] Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Grosshansdorf, Germany; German Centre for Lung Research, Grosshansdorf, Germany. Electronic address: mreck@lungenclinic.de.
          [2 ] Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.
          [3 ] Department of Oncology, Herlev University Hospital, Herlev, Denmark.
          [4 ] Department of Medical Oncology, Centre ICO René Gauducheau, Nantes, France.
          [5 ] Department of Thoracic Oncology, St Petersburg State Medical University, St Petersburg, Russia.
          [6 ] The Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland.
          [7 ] Pneumology Clinic, Asklepios Fachkliniken Munchen-Gauting, Gauting, Germany.
          [8 ] Lung Cancer Unit, Meir Medical Centre, Kfar Saba, Israel.
          [9 ] Clinical Facility, Dnepropetrovsk Medical Academy, Dnepropetrovsk Municipal Clinical Hospital no 4, Dnepropetrovsk, Ukraine.
          [10 ] Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
          [11 ] Department of Medical Affairs, Boehringer Ingelheim Pharma, Ingelheim, Germany.
          [12 ] Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
          [13 ] Medical Data Services and Biostatistics, Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.
          [14 ] Department of Oncology, University of Turin, AUO San Luigi, Orbassano, Italy.
          Article
          S1470-2045(13)70586-2
          10.1016/S1470-2045(13)70586-2
          24411639
          eeaee5c4-6c1d-4b2a-b918-d651c6f6510c
          Copyright © 2014 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article